ThirtyFiveBio Makes Its Debut With First-In-Class GPR35 Antagonist Approach

Targeting GI Diseases

 
• By Ayisha Sharma
Emerging Company Profile: ThirtyFiveBio
The Firm Will Likely Work On Colorectal Cancer As A First Indication • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs